FDA

FDA Articles

GW Pharmaceuticals won an FDA approval for its cannabis-derived drug, but shares were relatively muted on Thursday.
Calithera Biosciences receives a Fast Track designation for its kidney cancer treatment, sending shares higher.
Teligent watched its shares make a solid gain on Wednesday after the firm announced a key approval from the FDA.
Rigel Pharmaceuticals shares retreated early Wednesday despite an approval from the FDA for its treatment of thrombocytopenia.
GW Pharmaceuticals shares saw a solid gain on Tuesday after the FDA released some briefing documents pertaining to an upcoming approval meeting. Needless to say, investors are taking this as a...
Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S. and foreign biotechnology and pharmaceutical companies.
Bellicum Pharmaceuticals shares pulled back on Tuesday after the firm announced that it would be conducting a secondary offering to raise some cash.
The world of biotech can be a rags-to-riches story for companies that build up a drug candidate and secure FDA approval for that drug. And the larger the drug target group is, the more exciting it...
Shares of Alkermes saw a handy gain to start out the week after the FDA made a critical decision about its treatment for major depressive disorder.
Over the past week, a few biotech companies made absolutely massive runs, while others fell off a cliff. Although health care has barely kept pace with the broader markets over the past 52 weeks, the...
Bellicum Pharmaceuticals saw its shares rise early on Thursday after the firm announced a critical decision from the FDA.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) has found itself in the middle of a great opportunity but not being able to make the last mile of the race. Unfortunately, pain management in a non-opioid...
Proteostasis Therapeutics shares made a solid gain on Wednesday after a key FDA decision was announced.
Alkermes saw its shares drop early on Monday after the company announced that it received a Refusal to File letter from the FDA.
Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial and FDA updates in April.